Investor Presentation

9 Significant Market Opportunity for Lead Programs Systemic Sclerosis + ~200,000 patients in U.S., EU and Japan¹ ~$1.4B - $2.2B Lenabasum annual potential market opportunity¹ Lupus Dermatomyositis ~80,000 patients in U.S., EU and Japan¹ ~$1B - $2B Lenabasum annual potential market opportunity¹ Cystic Fibrosis + ~70,000 patients in U.S. and EU¹ 1: Health Advances, LLC; Lenabasum Commercial Market Assessment, peak annual revenue opportunity. ~$0.7 - $1B Lenabasum annual potential market opportunity¹ ~550,000 patient population in U.S., EU and Japan¹; ~$2B-$3B market opportunity¹ Significant Market Opportunity CRB-4001 Organ-specific fibrosis

View entire presentation